U.S.-Japan trade pact; Alphabet, Tesla to report - what’s moving markets
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $16.00 price target on Solid Biosciences (NASDAQ:SLDB) stock, which currently trades at $6.39 with a market capitalization of $495 million. The stock has shown strong momentum, gaining nearly 17% in the past week, according to InvestingPro data.
The research firm noted that 30-40% of patients have experienced liver enzyme elevations with ELEVIDYS treatment from Sarepta Therapeutics (NASDAQ:SRPT).
While Solid Biosciences’ data is at an earlier stage, the company has examined key biomarkers of liver injury such as GGT, which appear flat, according to Cantor Fitzgerald.
The firm highlighted that Solid Biosciences has also monitored biomarkers related to both liver health and muscle integrity, including AST, ALT, CK, and LDH, all of which show improvement.
Cantor Fitzgerald pointed out that Solid Biosciences’ construct is specifically designed to target cardiac and skeletal muscles while de-targeting the liver, using a capsid with RGD peptides that may also help with efficacy. InvestingPro analysis shows the company maintains a FAIR financial health score, with more cash than debt on its balance sheet. Investors should note the company’s next earnings report is scheduled for August 11, 2025.
In other recent news, Solid Biosciences has received FDA approval for its Investigational New Drug application for SGT-501, a gene therapy targeting catecholaminergic polymorphic ventricular tachycardia (CPVT). The company plans to initiate a Phase 1b clinical trial in late 2025 to evaluate the therapy’s safety and efficacy. Meanwhile, JMP Securities has reiterated its Market Outperform rating for Solid Biosciences, emphasizing the potential of its SGT-003 therapy for Duchenne muscular dystrophy (DMD) due to its differentiated capsid technology. Citi has also maintained a Buy rating, citing the safety profile of SGT-003 as a potential advantage over competitors like Sarepta’s Elevidys, which is under FDA investigation due to safety concerns. Cantor Fitzgerald has reiterated an Overweight rating, noting investor interest in Solid Biosciences’ pipeline, including SGT-212 for Friedreich’s ataxia and SGT-501 for CPVT. The company has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for SGT-501. Citi has also initiated coverage with a Buy rating, highlighting the significant market potential in DMD for Solid Biosciences. These developments reflect the company’s expanding focus beyond neuromuscular diseases to include cardiac indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.